Cargando…

Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and β(2)-agonist use

BACKGROUND: Vasodilator-stimulated phosphoprotein (VASP) mediates focal adhesion, actin filament binding and polymerization in a variety of cells, thereby inhibiting cell movement. Phosphorylation of VASP via cAMP and cGMP dependent protein kinases releases this "brake" on cell motility. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Hastie, Annette T, Wu, Min, Foster, Gayle C, Hawkins, Gregory A, Batra, Vikas, Rybinski, Katherine A, Cirelli, Rosemary, Zangrilli, James G, Peters, Stephen P
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1388207/
https://www.ncbi.nlm.nih.gov/pubmed/16480498
http://dx.doi.org/10.1186/1465-9921-7-25
_version_ 1782126898274369536
author Hastie, Annette T
Wu, Min
Foster, Gayle C
Hawkins, Gregory A
Batra, Vikas
Rybinski, Katherine A
Cirelli, Rosemary
Zangrilli, James G
Peters, Stephen P
author_facet Hastie, Annette T
Wu, Min
Foster, Gayle C
Hawkins, Gregory A
Batra, Vikas
Rybinski, Katherine A
Cirelli, Rosemary
Zangrilli, James G
Peters, Stephen P
author_sort Hastie, Annette T
collection PubMed
description BACKGROUND: Vasodilator-stimulated phosphoprotein (VASP) mediates focal adhesion, actin filament binding and polymerization in a variety of cells, thereby inhibiting cell movement. Phosphorylation of VASP via cAMP and cGMP dependent protein kinases releases this "brake" on cell motility. Thus, phosphorylation of VASP may be necessary for epithelial cell repair of damage from allergen-induced inflammation. Two hypotheses were examined: (1) injury from segmental allergen challenge increases VASP phosphorylation in airway epithelium in asthmatic but not nonasthmatic normal subjects, (2) regular in vivo β(2)-agonist use increases VASP phosphorylation in asthmatic epithelium, altering cell adhesion. METHODS: Bronchial epithelium was obtained from asthmatic and non-asthmatic normal subjects before and after segmental allergen challenge, and after regularly inhaled albuterol, in three separate protocols. VASP phosphorylation was examined in Western blots of epithelial samples. DNA was obtained for β(2)-adrenergic receptor haplotype determination. RESULTS: Although VASP phosphorylation increased, it was not significantly greater after allergen challenge in asthmatics or normals. However, VASP phosphorylation in epithelium of nonasthmatic normal subjects was double that observed in asthmatic subjects, both at baseline and after challenge. Regularly inhaled albuterol significantly increased VASP phosphorylation in asthmatic subjects in both unchallenged and antigen challenged lung segment epithelium. There was also a significant increase in epithelial cells in the bronchoalveolar lavage of the unchallenged lung segment after regular inhalation of albuterol but not of placebo. The haplotypes of the β(2)-adrenergic receptor did not appear to associate with increased or decreased phosphorylation of VASP. CONCLUSION: Decreased VASP phosphorylation was observed in epithelial cells of asthmatics compared to nonasthmatic normals, despite response to β-agonist. The decreased phosphorylation does not appear to be associated with a particular β(2)-adrenergic receptor haplotype. The observed decrease in VASP phosphorylation suggests greater inhibition of actin reorganization which is necessary for altering attachment and migration required during epithelial repair.
format Text
id pubmed-1388207
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-13882072006-03-04 Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and β(2)-agonist use Hastie, Annette T Wu, Min Foster, Gayle C Hawkins, Gregory A Batra, Vikas Rybinski, Katherine A Cirelli, Rosemary Zangrilli, James G Peters, Stephen P Respir Res Research BACKGROUND: Vasodilator-stimulated phosphoprotein (VASP) mediates focal adhesion, actin filament binding and polymerization in a variety of cells, thereby inhibiting cell movement. Phosphorylation of VASP via cAMP and cGMP dependent protein kinases releases this "brake" on cell motility. Thus, phosphorylation of VASP may be necessary for epithelial cell repair of damage from allergen-induced inflammation. Two hypotheses were examined: (1) injury from segmental allergen challenge increases VASP phosphorylation in airway epithelium in asthmatic but not nonasthmatic normal subjects, (2) regular in vivo β(2)-agonist use increases VASP phosphorylation in asthmatic epithelium, altering cell adhesion. METHODS: Bronchial epithelium was obtained from asthmatic and non-asthmatic normal subjects before and after segmental allergen challenge, and after regularly inhaled albuterol, in three separate protocols. VASP phosphorylation was examined in Western blots of epithelial samples. DNA was obtained for β(2)-adrenergic receptor haplotype determination. RESULTS: Although VASP phosphorylation increased, it was not significantly greater after allergen challenge in asthmatics or normals. However, VASP phosphorylation in epithelium of nonasthmatic normal subjects was double that observed in asthmatic subjects, both at baseline and after challenge. Regularly inhaled albuterol significantly increased VASP phosphorylation in asthmatic subjects in both unchallenged and antigen challenged lung segment epithelium. There was also a significant increase in epithelial cells in the bronchoalveolar lavage of the unchallenged lung segment after regular inhalation of albuterol but not of placebo. The haplotypes of the β(2)-adrenergic receptor did not appear to associate with increased or decreased phosphorylation of VASP. CONCLUSION: Decreased VASP phosphorylation was observed in epithelial cells of asthmatics compared to nonasthmatic normals, despite response to β-agonist. The decreased phosphorylation does not appear to be associated with a particular β(2)-adrenergic receptor haplotype. The observed decrease in VASP phosphorylation suggests greater inhibition of actin reorganization which is necessary for altering attachment and migration required during epithelial repair. BioMed Central 2006 2006-02-15 /pmc/articles/PMC1388207/ /pubmed/16480498 http://dx.doi.org/10.1186/1465-9921-7-25 Text en Copyright © 2006 Hastie et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Hastie, Annette T
Wu, Min
Foster, Gayle C
Hawkins, Gregory A
Batra, Vikas
Rybinski, Katherine A
Cirelli, Rosemary
Zangrilli, James G
Peters, Stephen P
Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and β(2)-agonist use
title Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and β(2)-agonist use
title_full Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and β(2)-agonist use
title_fullStr Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and β(2)-agonist use
title_full_unstemmed Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and β(2)-agonist use
title_short Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and β(2)-agonist use
title_sort alterations in vasodilator-stimulated phosphoprotein (vasp) phosphorylation: associations with asthmatic phenotype, airway inflammation and β(2)-agonist use
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1388207/
https://www.ncbi.nlm.nih.gov/pubmed/16480498
http://dx.doi.org/10.1186/1465-9921-7-25
work_keys_str_mv AT hastieannettet alterationsinvasodilatorstimulatedphosphoproteinvaspphosphorylationassociationswithasthmaticphenotypeairwayinflammationandb2agonistuse
AT wumin alterationsinvasodilatorstimulatedphosphoproteinvaspphosphorylationassociationswithasthmaticphenotypeairwayinflammationandb2agonistuse
AT fostergaylec alterationsinvasodilatorstimulatedphosphoproteinvaspphosphorylationassociationswithasthmaticphenotypeairwayinflammationandb2agonistuse
AT hawkinsgregorya alterationsinvasodilatorstimulatedphosphoproteinvaspphosphorylationassociationswithasthmaticphenotypeairwayinflammationandb2agonistuse
AT batravikas alterationsinvasodilatorstimulatedphosphoproteinvaspphosphorylationassociationswithasthmaticphenotypeairwayinflammationandb2agonistuse
AT rybinskikatherinea alterationsinvasodilatorstimulatedphosphoproteinvaspphosphorylationassociationswithasthmaticphenotypeairwayinflammationandb2agonistuse
AT cirellirosemary alterationsinvasodilatorstimulatedphosphoproteinvaspphosphorylationassociationswithasthmaticphenotypeairwayinflammationandb2agonistuse
AT zangrillijamesg alterationsinvasodilatorstimulatedphosphoproteinvaspphosphorylationassociationswithasthmaticphenotypeairwayinflammationandb2agonistuse
AT petersstephenp alterationsinvasodilatorstimulatedphosphoproteinvaspphosphorylationassociationswithasthmaticphenotypeairwayinflammationandb2agonistuse